BPC-157

Healing & recovery Research compound (not approved for human use)

Synthetic pentadecapeptide · also known as BPC 157, Body Protection Compound-157

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

BPC-157 is a synthetic peptide derived from a sequence found in gastric juice. It is one of the most widely discussed research peptides in tissue-repair research and is frequently paired with TB-500 in recovery-oriented protocols.

Commonly reported dosing by vial size

Frequency: Once daily, subcutaneous (some reports split it into two injections) · Half-life: Short (minutes to a few hours, route dependent)

Vial size (4 sizes)5 mg10 mg20 mg40 mg

5 mg vial + 3 mL → 1.67 mg per mL

Diluent: bacteriostatic water (as commonly reported)

The 5 mg vial is commonly reconstituted with 3 mL.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 5 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 1.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Commonly reported dosing

Phase	Dose	Volume	U-100 units
Starting Weeks 1-2	200 mcg	0.12 mL	12
Standard Weeks 3-4	400 mcg	0.24 mL	24
Higher Weeks 5-8 and beyond	600 mcg	0.36 mL	36

Open in calculator (5 mg + 3 mL)

10 mg vial + 3 mL → 3.33 mg per mL

Diluent: bacteriostatic water (as commonly reported)

The 10 mg vial is commonly reconstituted with 3 mL.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 3.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Commonly reported dosing

Phase	Dose	Volume	U-100 units
Starting Weeks 1-2	200 mcg	0.06 mL	6
Standard Weeks 3-4	400 mcg	0.12 mL	12
Higher Weeks 5-8 and beyond	600 mcg	0.18 mL	18

Open in calculator (10 mg + 3 mL)

20 mg vial + 3 mL → 6.67 mg per mL

Diluent: bacteriostatic water (as commonly reported)

The 20 mg vial is commonly reconstituted with 3 mL.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 20 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 6.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Commonly reported dosing

Phase	Dose	Volume	U-100 units
Starting Weeks 1-2	200 mcg	0.03 mL	3
Standard Weeks 3-4	400 mcg	0.06 mL	6
Higher Weeks 5-8 and beyond	600 mcg	0.09 mL	9

Open in calculator (20 mg + 3 mL)

40 mg vial + 3 mL → 13.33 mg per mL

Diluent: bacteriostatic water (as commonly reported)

The 40 mg vial is commonly reconstituted with 3 mL.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 40 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 13.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Commonly reported dosing

Phase	Dose	Volume	U-100 units
Starting Weeks 1-2	200 mcg	0.015 mL	1.5 (warning)
Standard Weeks 3-4	400 mcg	0.03 mL	3
Higher Weeks 5-8 and beyond	600 mcg	0.045 mL	4.5

⚠ Under 2 units on a U-100 syringe at this concentration, which is hard to measure reliably.

Open in calculator (40 mg + 3 mL)

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

Research suggests BPC-157 may influence angiogenesis and growth-factor signaling (for example the VEGF pathway), which are associated with tissue repair processes in preclinical models.

Researched for

Studied for tendon, ligament, and soft-tissue healing in animal models.
Investigated for gastrointestinal protective effects.
Commonly combined with TB-500 in recovery research stacks.

Notes

Dosing is typically expressed in micrograms, which are small volumes on a U-100 syringe.
Human clinical evidence is limited; most data are preclinical, so the amounts shown are community-reported rather than trial-derived.

Sources

Last reviewed 2026-10-06.

TB-500

Thymosin beta-4 fragment

TB-500 is a synthetic version of a region of the naturally occurring protein thymosin beta-4.

5 mg vial · Once daily, subcutaneous (a weekly loading pattern is also reported)

BPC-157 + TB-500 20 mg Blend

Tissue-repair research blend (BPC-157 + TB-500)

This blend combines BPC-157 and TB-500 in a single vial (20 mg by default, with a 10 mg size also listed), a common pairing in recovery-oriented research because the two peptides are studied for complementary roles in tissue-repair research.

20 mg vial · Once daily, subcutaneous